TaiGen Biopharmaceuticals Holdings Limited (TPEX:4157)
Taiwan · Delayed Price · Currency is TWD 13.85
-0.20 (-1.42%)
Jan 22, 2026, 10:40 AM CST
TPEX:4157 Revenue
TaiGen Biopharmaceuticals Holdings had revenue of 6.68M TWD in the quarter ending September 30, 2025, a decrease of -22.47%. This brings the company's revenue in the last twelve months to 38.75M, down -73.95% year-over-year. In the year 2024, TaiGen Biopharmaceuticals Holdings had annual revenue of 150.65M with 22.35% growth.
Revenue (ttm)
38.75M
Revenue Growth
-73.95%
P/S Ratio
258.12
Revenue / Employee
n/a
Employees
n/a
Market Cap
10.00B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 150.65M | 27.52M | 22.35% |
| Dec 31, 2023 | 123.13M | 86.90M | 239.87% |
| Dec 31, 2022 | 36.23M | -1.26B | -97.20% |
| Dec 31, 2021 | 1.29B | 1.27B | 5,426.95% |
| Dec 31, 2020 | 23.42M | 3.11M | 15.30% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| PharmaEngine | 2.51B |
| Adimmune | 1.20B |
| Ever Supreme Bio Technology | 1.01B |
| TCM Biotech International | 682.40M |
| Mycenax Biotech | 649.64M |
| Medigen Vaccine Biologics | 594.96M |
| Tanvex BioPharma | 224.83M |
| OBI Pharma | 49.29M |